Skip to main content

Table 2 Univariate analyses for progression-free survival

From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Characteristics No. (%) Median PFS, month HR (95% CI) P value
(n = 88)
Age, years
  ≥ 75 26 (30) 10.0 1.96 (1.11–3.47) 0.020*
  < 75 62 (70) 20.6 Reference
Sex
 female 14 (16) 17.5 1.02 (0.42–2.14) 0.955
 male 74 (84) 18.4 Reference
Smoking status
 smoker (current or former) 78 (89) 18.2 1.25 (0.57–3.29) 0.615
 never smoker 10 (11) 18.4 Reference
ECOG PS
 2–4 13 (15) 8.7 2.65 (1.24–5.17) 0.007*
 0–1 75 (85) 19.6 Reference
Histology
 Squamous 24 (27) 15.2 1.17 (0.63–2.17) 0.624
 Non-squamous 64 (73) 18.1 Reference
Stage
 IV 67 (76) 17.7 1.19 (0.63–2.45) 0.605
 IIIB 21 (24) 19.7 Reference
Pleural effusion or dissemination
 present 21 (24) 18.5 0.88 (0.47–1.63) 0.685
 absent 67 (76) 18.2 Reference
Bone metastasis
 present 26 (30) 9.3 3.71 (2.04–6.73) < 0.001*
 absent 62 (70) 23.2 Reference
Brain metastasis     
 present 11 (13) 19.6 0.93 (0.39–2.18) 0.858
 absent 77 (88) 18.4 Reference
Adrenal grand metastasis     
 present 14 (16) 18.4 0.95 (0.44–2.02) 0.886
 absent 74 (84) 18.2 Reference
Liver metastasis
 present 14 (16) 19.6 0.78 (0.35–1.75) 0.543
 absent 74 (84) 17.9 Reference
Number of metastatic organs
  ≥ 3 16 (18) 16.4 2.37 (1.20–4.41) 0.009*
  < 3 72 (82) 20.6 Reference
Early irAEs
 present 41 (47) 17.5 1.05 (0.60–1.84) 0.857
 absent 47 (53) 19.6 Reference
  1. * P < 0.05
  2. PFS progression-free survival, ECOG PS Eastern Cooperative Oncology Group performance status, irAE immune-related adverse event, HR hazard ratio, PFS progression-free survival
\